Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004248 · ClinicalTrials.gov registry record · Phase 2

Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

A Phase 2 study of Liver Cancer, sponsored by Roswell Park Cancer Institute.

Completed
Registry status
Phase 2
Development phase
24
Enrollment target
1
Study location

NCT00004248 is a Phase 2 study of Liver Cancer that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 24 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004248, a Phase 2 study of Liver Cancer, has completed, sponsored by Roswell Park Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill liver cancer cells. PURPOSE: Phase II trial to study the effectiveness of doxorubicin and interleukin- 2 in treating patients who have liver cancer that cannot be removed by surgery.

Conditions Studied

Liver Cancer

Interventions

  • BIOLOGICAL aldesleukin
  • DRUG doxorubicin hydrochloride

Study Locations (1)

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 1999-07
Est. Completion 2001-05
Phase Phase 2

Sponsor

Roswell Park Cancer Institute

365 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00004248

The ClinicalTrials.gov registry entry for NCT00004248 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 2 interventions - of which aldesleukin is the first listed.

NCT00004248 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00004248 about?

NCT00004248 is a clinical study titled "Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill liver cancer cells. PURPOSE: Phase II trial to study the effectiveness of doxorubicin and interleukin- 2 in treati...

What is the current status of trial NCT00004248?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 1999-07. Estimated completion is 2001-05.

What conditions does trial NCT00004248 study?

This clinical trial studies the following conditions: Liver Cancer.

What interventions are being tested in trial NCT00004248?

The interventions under investigation include: aldesleukin (BIOLOGICAL), doxorubicin hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00004248?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00004248 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Liver Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Liver Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.